Scilex Holding Company Announces that Its Note Holders Intend to Participate in the Funding and Licensing of Gloperba® Ex-U.S. Commercialization Rights from Romeg Therapeutics, LLC

Core Viewpoint - Scilex Holding Company is advancing its strategy to commercialize non-opioid pain management products and has announced a joint venture with IPMC Company to enhance its capabilities in treating neurodegenerative and cardiometabolic diseases [1][3]. Company Overview - Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain [3][4]. - The company is headquartered in Palo Alto, California [5]. Product Portfolio - Scilex's commercial products include: - ZTlido (lidocaine topical system) 1.8%, approved by the FDA for neuropathic pain relief [3]. - ELYXYB, the only FDA-approved ready-to-use oral solution for acute migraine treatment in adults [3]. - Gloperba, the first liquid oral version of colchicine for the prophylaxis of painful gout flares [3][11]. - The company has three product candidates in development: - SP-102 (SEMDEXA™), a viscous gel for epidural injections to treat lumbosacral radicular pain, which has completed a Phase 3 study [4]. - SP-103, a next-generation lidocaine topical system for acute pain, recently completed a Phase 2 trial [4]. - SP-104, a low-dose naltrexone hydrochloride for fibromyalgia treatment [4]. Recent Developments - Existing Tranche B senior secured convertible note holders intend to participate in funding and licensing Gloperba's ex-U.S. commercialization rights from Romeg Therapeutics, LLC [1]. - The note holders will also manage the worldwide licensing and distribution of Gloperba through a joint venture [1].